Warning: Declaration of subscribe2_widget::addPluginSubMenu() should be compatible with mijnpress_plugin_framework::addPluginSubMenu($title, $function, $file, $capability = 10, $where = 'plugins.ph...') in /data/32/2/10/97/2499423/user/2737425/htdocs/wordpress1/wp-content/plugins/subscribe2-widget/subscribe2-widget.php on line 18

Warning: Declaration of subscribe2_widget::addPluginContent($links, $file) should be compatible with mijnpress_plugin_framework::addPluginContent($filename, $links, $file, $config_url = NULL) in /data/32/2/10/97/2499423/user/2737425/htdocs/wordpress1/wp-content/plugins/subscribe2-widget/subscribe2-widget.php on line 18
Early Stage Emerging Biotech, Pharma, & Medical Device Companies Announced | SEBIO

Early Stage Emerging Biotech, Pharma, & Medical Device Companies Announced

Posted by on Oct 23, 2019

Innovative drug therapies, advanced medical devices, diagnostics, and other cutting-edge healthcare technologies from throughout the Southeast will be showcased November 6-7 at the Southeast BIO Investor & Partnering Forum at the historic Biltmore Hotel in Coral Gables, Florida.

Innovative drug therapies, advanced medical devices, diagnostics, and other cutting-edge healthcare technologies from throughout the Southeast will be showcased November 6-7 at the Southeast BIO Investor & Partnering Forum at the historic Biltmore Hotel in Coral Gables, Florida. Register today.

Entrepreneurs representing the most promising early stage bioscience and medical technology
companies in the region will solicit advice and seek investment during the annual life science
convention sponsored by Southeast BIO, the regional nonprofit organization dedicated to
fostering the growth of the southeast’s life sciences industry. The companies were picked by a
selection committee of regional and national venture capitalists.

Early Stage companies will participate in forty-minute individual private advisory sessions behind
closed doors with teams of investors, business advisors, service providers and successful
entrepreneurs Wednesday, November 6.

Companies chosen for the Early Stage event are seeking their first rounds of institutional
investment. The four best Early Stage companies will be selected to present to the full
conference audience during the Early Stage Competition, with an overall winner announced at the lunch on Thursday, November 7.

“We are excited about this year’s group of Early Stage companies. They represent the Southeast
region’s scientific diversity and entrepreneurial activity,” said Doug Gooding of Knowles Intellectual Property Strategies, Early Stage Program Co-Chair, along with Mike Dial, PhD of Hatteras Venture Partners.

Early Stage companies chosen to present at this year’s Forum are:

Achelios Therapeutics (Chapel Hill, NC) clinical-stage specialty pharmaceutical company developing proprietary topical formulations of non-steroidal anti-inflammatory drug (NSAID) molecules to treat pain and inflammation

AMPEL BioSolutions, LLC (Charlottesville, VA) technology company with CRO capabilities combining genomic technologies with advanced analytics to develop the Clinical Genomic Blood Test to match patients to the best therapy in clinical trials and clinical care

Ares Immunotherapy (Atlanta, GA) pre-clinical adoptive T cell therapy company based on technology discovered at the Medical University of South Carolina developing CD26+ CAR-T cells therapy specific for mesothelin for the treatment of mesothelioma and other solid tumors

Azure 8 (Atlanta, GA) medical device company developing the Sonix-A8TM, a Class II medical device to prevent and control surgical site and catheter-related bacterial infections

Cathaid (Augusta, GA) medical device company developing CathaidTM, a Class I medical device to better secure central venous catheters which allows real time detection of dangerous positional shifts and reduces infection

DermaSensor (Miami, FL) medical device company developing a handheld wireless medical device for dermatologists that uses electron scattering microscopy combined with a proprietary algorithm to evaluate skin lesions for potential skin cancer

EDP Biotech, Inc. (Knoxville, TN) ISO-certified in vitro diagnostics company focused on the commercialization of ColoPlex™, a blood-based test aimed at early detection of colorectal cancer

Evren Technologies (Newberry, FL) medical device company based on technology discovered at the University of Florida that is developing the PhoenixTM, a wearable device that provides transcutaneous vagal nerve stimulation for the treatment of post-traumatic stress disorder

IMMvention Therapeutix (Durham, NC) drug discovery start-up based on technology discovered at the University of North Carolina, Chapel Hill that is developing a pre-clinical pipeline of proprietary innate immunity specific therapies for autoimmune and inflammatory diseases 

Inquisatex Epitherapeutics (Charleston, SC) drug discovery start-up based on technology discovered at the Medical University of South Carolina developing a novel series of compounds for the treatment of Sickle Cell Disease.

KeViRx (Charlottesville, VA) pre-clinical oncology company based on technology discovered at the University of Virginia and the University of Pittsburgh developing KVR-053, an allosteric PTP4A3 phosphatase small molecule inhibitor for ovarian, colorectal and breast cancers.

Oracle Health (Tampa, FL) medical device company developing a Digital Health enabled Insertable Cardiac Monitor (ICM) to follow Heart Failure progression and prevent Heart Failure hospitalization

Oxidien Pharmaceuticals (Gainesville, FL) clinical stage drug development company with proprietary enzyme assets to treat hyperoxaluria, a severe and debilitating condition causing renal damage, progressive chronic kidney disease, and end-stage renal failure

Park Surgical Innovations (Atlanta, GA) medical device company developing the Park Surgical Graft Delivery System, a class II medical device and method for delivering a prosthetic graft for laparoscopic ventral hernia repair

Plakous Therapeutics (Winston-Salem, NC) pre-clinical regenerative medicine company developing Protego-PD™, an acellular placental derived platform product for the treatment of necrotizing enterocolitis (NEC) and osteoarthritis (OA)

Pyrefin, Inc. (Atlanta, GA) pre-clinical drug discovery company based on technology discovered at Emory University developing orally-active small molecule antagonists of the prostaglandin E2 (EP2) receptor for the treatment of pain and inflammation

https://bit.ly/368rxXs

 

Leave a Reply